589 related articles for article (PubMed ID: 28130773)
1. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.
Trippe ZA; Brendani B; Meier C; Lewis D
Drug Saf; 2017 Apr; 40(4):293-303. PubMed ID: 28130773
[TBL] [Abstract][Full Text] [Related]
2. Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine.
Martin D; Menschik D; Bryant-Genevier M; Ball R
Drug Saf; 2013 Jul; 36(7):547-56. PubMed ID: 23657824
[TBL] [Abstract][Full Text] [Related]
3. Using VigiBase to Identify Substandard Medicines: Detection Capacity and Key Prerequisites.
Juhlin K; Karimi G; Andér M; Camilli S; Dheda M; Har TS; Isahak R; Lee SJ; Vaughan S; Caduff P; Norén GN
Drug Saf; 2015 Apr; 38(4):373-82. PubMed ID: 25687792
[TBL] [Abstract][Full Text] [Related]
4. Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker.
Berlin C; Blanch C; Lewis DJ; Maladorno DD; Michel C; Petrin M; Sarp S; Close P
Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):622-30. PubMed ID: 21994119
[TBL] [Abstract][Full Text] [Related]
5. Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles.
Bailey S; Singh A; Azadian R; Huber P; Blum M
Drug Saf; 2010 Feb; 33(2):139-46. PubMed ID: 20082540
[TBL] [Abstract][Full Text] [Related]
6. Analysis of pharmacovigilance databases for spontaneous reports of adverse drug reactions related to substandard and falsified medical products: A descriptive study.
Pozsgai K; Szűcs G; Kőnig-Péter A; Balázs O; Vajda P; Botz L; Vida RG
Front Pharmacol; 2022; 13():964399. PubMed ID: 36147337
[No Abstract] [Full Text] [Related]
7. The Social Impact of Suspected Adverse Drug Reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database.
Castillon G; Salvo F; Moride Y
Drug Saf; 2019 Jan; 42(1):27-34. PubMed ID: 30121742
[TBL] [Abstract][Full Text] [Related]
8. Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase.
Star K; Norén GN; Nordin K; Edwards IR
Drug Saf; 2011 May; 34(5):415-28. PubMed ID: 21513364
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
[TBL] [Abstract][Full Text] [Related]
10. The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review.
Dias P; Penedones A; Alves C; Ribeiro CF; Marques FB
Curr Drug Saf; 2015; 10(3):234-50. PubMed ID: 26219291
[TBL] [Abstract][Full Text] [Related]
11. An experimental investigation of masking in the US FDA adverse event reporting system database.
Wang HW; Hochberg AM; Pearson RK; Hauben M
Drug Saf; 2010 Dec; 33(12):1117-33. PubMed ID: 21077702
[TBL] [Abstract][Full Text] [Related]
12. Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures.
Ang PS; Chen Z; Chan CL; Tai BC
Expert Opin Drug Saf; 2016 May; 15(5):583-90. PubMed ID: 26996192
[TBL] [Abstract][Full Text] [Related]
13. Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database.
Berbain T; Pariente A; Miremont-Salamé G; Grandvuillemin A; Micallef J; Chouchana L; Benkebil M; Théophile H;
Drug Saf; 2020 Mar; 43(3):243-253. PubMed ID: 31974775
[TBL] [Abstract][Full Text] [Related]
14. Suspected adverse reactions reported for blood, blood components, and blood products in VigiBase.
Samukange WT; Lu TA; Souverein PC; Gardarsdottir H; Mantel-Teeuwisse AK
Transfusion; 2023 May; 63(5):982-992. PubMed ID: 36994873
[TBL] [Abstract][Full Text] [Related]
15. Profile of adverse drug reaction reports in South Africa: An analysis of VigiBase® for the year 2017.
Steyn H
S Afr Med J; 2023 Jun; 113(6):26-33. PubMed ID: 37278262
[TBL] [Abstract][Full Text] [Related]
16. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
Shu Y; Ding Y; Dai B; Zhang Q
Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
[TBL] [Abstract][Full Text] [Related]
17. IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis.
Alroobaea R; Rubaiee S; Hanbazazah AS; Jahrami H; Garbarino S; Damiani G; Wu J; Bragazzi NL
Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):4074-4081. PubMed ID: 35731078
[TBL] [Abstract][Full Text] [Related]
18. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
[TBL] [Abstract][Full Text] [Related]
19. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports.
Conte C; Rousseau V; Vert C; Montastruc F; Montastruc JL; Durrieu G; Olivier P
Fundam Clin Pharmacol; 2020 Aug; 34(4):518-520. PubMed ID: 32022302
[TBL] [Abstract][Full Text] [Related]
20. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
